Impact of different postoperative adjuvant therapies on the survival of early-stage cervical cancer patients with one intermediate-risk factor: A multicenter study of 14 years

被引:7
|
作者
Ye, Yanna [1 ,2 ]
Li, Zhiqiang [1 ]
Kang, Shan [3 ]
Zhan, Xuemei [4 ]
Zhang, Yi [5 ]
Xu, Yan [6 ]
Li, Weili [2 ]
Lang, Jinghe [2 ,7 ]
Liu, Ping [2 ]
Chen, Chunlin [1 ,2 ]
机构
[1] Southern Med Univ, Nanfang Hosp, Dept Obstet & Gynecol, 1838 Guangzhou Ave, Guangzhou 510515, Peoples R China
[2] Dongguan Polytech, Fac Hlth, Dept Midwifery, Dongguan, Peoples R China
[3] Hebei Med Univ, Hosp 4, Dept Gynecol, Shijiazhuang, Peoples R China
[4] SEN Univ, Affiliated Jiangmen Hosp SUN YAT, Dept Obstet & Gynecol, Jiangmen, Peoples R China
[5] China Med Univ, Dept Gynecol, Hosp 1, Shenyang, Peoples R China
[6] Pan Yu Cent Hosp, Dept Obstet & Gynecol, Guangzhou, Peoples R China
[7] Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
cervical cancer; disease-free survival; intermediate-risk pathological factor; oncological outcome; overall survival; postoperative adjuvant therapy; RADICAL HYSTERECTOMY; PELVIC IRRADIATION; RADIATION-THERAPY; RANDOMIZED-TRIAL; CARCINOMA; CHEMOTHERAPY; IB; RADIOTHERAPY; CISPLATIN; METASTASIS;
D O I
10.1111/jog.15632
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare survival outcomes of different postoperative adjuvant therapies (PATs) for early-stage cervical cancer (ECC) patients with one intermediate-risk pathological factor (IPF).Methods: A total of 2889 patients with stage IA1 to IIA2 cervical cancer were included in this study. Three PAT groups were identified, namely a no adjuvant therapy (NAT) group (n = 773), an adjuvant radiotherapy/chemoradiotherapy (ART) group (n = 1648) and an adjuvant chemotherapy (ACT) group (n = 468). Kaplan-Meier analysis and COX regression analysis were used to compare the overall survival (OS) and disease-free survival (DFS) among the three groups, before and after propensity score matching (PSM).Results: The recurrence and mortality rate rates in the NAT, ART and ACT groups were 9.2%, 8.6%, and 7.9%, respectively (p = 0.737). Kaplan-Meier analysis demonstrated no significant differences in the NAT, ART, and ACT groups in 5-year OS rates (92.8% vs. 93.6% vs. 94.7%, p = 0.594) and DFS rates (88.7% vs. 89.6% vs. 90.5%, p = 0.772). Post-hoc tests yielded similar results, with no differences in 5-year OS and DFS (NAT vs. ART, before and after matching, p > 0.05); (NAT vs. ACT, before and after matching, p > 0.05); and (ACT vs. ART, before and after matching, p > 0.05).Conclusion: Postoperative adjuvant radiotherapy, chemoradiotherapy, and chemotherapy are not associated with survival outcomes of ECC patients with one IPF. Considering the side effects and impact on patients' quality of life, the PATs should be carefully considered.
引用
收藏
页码:1579 / 1591
页数:13
相关论文
共 50 条
  • [1] Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer
    Cao, Lijie
    Wen, Hao
    Feng, Zheng
    Han, Xiaotian
    Zhu, Jun
    Wu, Xiaohua
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 52 - 58
  • [2] Postoperative adjuvant chemotherapy combined with intracavitary brachytherapy in early-stage cervical cancer patients with intermediate risk factors
    Yu, Hao
    Zhang, Linlin
    Du, Xuelian
    Sheng, Xiugui
    ONCOTARGETS AND THERAPY, 2016, 9 : 7331 - 7335
  • [3] Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer
    Nishimura, Hiroki
    Amano, Tsukuru
    Yoneoka, Yutaka
    Tsuji, Shunichiro
    Taga, Yukiko
    Aki, Megumi
    Uno, Masaya
    Moritani, Suzuko
    Murakami, Ryusuke
    Kato, Tomoyasu
    Murakami, Takashi
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2025, 36 (01)
  • [4] Impact of Adjuvant Radiotherapy on Survival Outcomes in Intermediate-Risk, Early-Stage Cervical Cancer: Analyses Regarding Surgical Approach of Radical Hysterectomy
    Kim, Se Ik
    Kim, Tae Hun
    Lee, Maria
    Kim, Hee Seung
    Chung, Hyun Hoon
    Lee, Taek Sang
    Jeon, Hye Won
    Kim, Jae-Weon
    Park, Noh Hyun
    Song, Yong Sang
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 11
  • [5] Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study
    Cibula, David
    Akilli, Huseyin
    Jarkovsky, Jiri
    van Lonkhuijzen, Luc
    Scambia, Giovanni
    Meydanli, Mehmet Mutlu
    Ortiz, David Isla
    Falconer, Henrik
    Abu-Rustum, Nadeem R.
    Odetto, Diego
    Klat, Jaroslav
    dos Reis, Ricardo
    Zapardiel, Ignacio
    Di Martino, Giampaolo
    Presl, Jiri
    Laky, Rene
    Lopez, Aldo
    Weinberger, Vit
    Obermair, Andreas
    Pareja, Rene
    Poncova, Renata
    Mom, Constantijne
    Bizzarri, Nicolo
    Borcinova, Martina
    Aslan, Koray
    Hernandez, Rosa Angelica Salcedo
    Fons, Guus
    Benesova, Klara
    Dostalek, Lukas
    Ayhan, Ali
    GYNECOLOGIC ONCOLOGY, 2023, 170 : 195 - 202
  • [6] Assessment of postoperative therapy de-escalation for early-stage, intermediate-risk cervical cancer
    Matsuo, Koji
    Shimada, Muneaki
    Matsuzaki, Shinya
    Machida, Hiroko
    Shigeta, Shogo
    Yoshida, Hiroshi
    Kato, Kazuyoshi
    Kanao, Hiroyuki
    Takekuma, Munetaka
    Mikami, Mikio
    Okamoto, Aiko
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (09) : 1349 - 1358
  • [7] Impact of preoperative leukocyte alteration in surgically-treated early-stage cervical cancer patients with low-risk, intermediate-risk or high-risk factors
    Matsumoto, Y.
    Mabuchi, S.
    Kozasa, K.
    Kuroda, H.
    Sasano, T.
    Yokoi, E.
    Sawada, K.
    Kimura, T.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2018, 39 (06) : 939 - 946
  • [8] Comparison of chemoradiation with radiation as postoperative adjuvant therapy in cervical cancer patients with intermediate-risk factors
    Kim, K.
    Kang, S. B.
    Chung, H. H.
    Kim, J. W.
    Park, N. H.
    Song, Y. S.
    EJSO, 2009, 35 (02): : 192 - 196
  • [9] Postoperative treatment of intermediate-risk early stage cervical cancer: results of a survey from the Gynecology Study Group in the AIRO Gyn and MITO Groups
    Perrucci, Elisabetta
    Cerrotta, Annamaria
    Macchia, Gabriella
    Augurio, Antonietta
    Campitelli, Maura
    De Sanctis, Vitaliana
    Lazzari, Roberta
    Magri, Elena
    Marsella, Anna Rita
    Meregalli, Sofia
    Tamburo, Marinella
    Ferrandina, Gabriella
    Aristei, Cynthia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 174
  • [10] Comparison of adjuvant chemoradiotherapy versus radiotherapy in early-stage cervical cancer patients with intermediate-risk factors: A systematic review and meta-analysis
    Guo, Qingmin
    Wang, Rui
    Jin, Dongmei
    Yin, Zhengfang
    Hu, Bao
    Li, Ruifeng
    Wu, Dongyue
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2022, 61 (01): : 15 - 23